Last reviewed · How we verify
Revacept
Revacept is a Small molecule drug developed by AdvanceCor GmbH. It is currently in Phase 2 development. Also known as: 40 mg or 120 mg.
Revacept is a novel inhibitor of platelet adhesion being studied for the treatment of various cardiovascular conditions, including stable coronary artery disease, carotid stenosis, atherosclerosis, stroke, and transient-ischaemic attack. It is administered in doses of 80 mg and 160 mg, and is being compared to a placebo in clinical trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Revacept |
|---|---|
| Also known as | 40 mg or 120 mg |
| Sponsor | AdvanceCor GmbH |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Revacept in Symptomatic Carotid Stenosis (PHASE2)
- Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept (PHASE2)
- Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Revacept CI brief — competitive landscape report
- Revacept updates RSS · CI watch RSS
- AdvanceCor GmbH portfolio CI
Frequently asked questions about Revacept
What is Revacept?
Who makes Revacept?
Is Revacept also known as anything else?
What development phase is Revacept in?
Related
- Manufacturer: AdvanceCor GmbH — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: 40 mg or 120 mg
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing